Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium

Virchows Arch. 1994;424(6):631-4. doi: 10.1007/BF00195777.


Immunohistochemical study of bcl-2 protein immunoreactivity in human non-neoplastic mesothelium (44 cases) and in malignant mesothelioma (62 cases) using a murine monoclonal antibody (clone 124) showed cytoplasmic immunoreactivity for bcl-2 protein in five cases of malignant mesothelioma. Non-neoplastic mesothelium was not immunoreactive. Immunoreactivity for bcl-2 protein does not add useful prognostic information in malignant mesothelioma since survival times of bcl-2 positive and bcl-2 negative cases did not differ. Nevertheless, the detection of bcl-2 protein in malignant mesothelioma might be useful for the differentiation from reactive mesothelium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epithelium / chemistry
  • Humans
  • Immunohistochemistry
  • Mesothelioma / chemistry*
  • Mesothelioma / mortality
  • Proto-Oncogene Proteins / analysis*
  • Proto-Oncogene Proteins c-bcl-2
  • Survival Rate


  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2